These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19261344)

  • 21. Valuing life: a plea for disaggregation.
    Sunstein CR
    Duke Law J; 2004 Nov; 54(2):385-445. PubMed ID: 15940845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conjoint analysis. The cost variable: an Achilles' heel?
    Slothuus Skjoldborg U; Gyrd-Hansen D
    Health Econ; 2003 Jun; 12(6):479-91. PubMed ID: 12759917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comorbidities and the willingness to pay for reducing the risk of a targeted disease: introducing endogenous effort for risk reduction.
    Liu L
    Health Econ; 2004 May; 13(5):493-8. PubMed ID: 15127428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The value of a statistical life: theoretical and empirical evidence.
    Johansson PO
    Appl Health Econ Health Policy; 2002; 1(1):33-41. PubMed ID: 14618746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of risk representation and scope on willingness to pay for reduced risks: evidence from Tokyo Bay, Japan.
    Zhai G; Suzuki T
    Risk Anal; 2008 Apr; 28(2):513-22. PubMed ID: 18419666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Willingness to pay for safe drinking water: Evidence from Parral, Mexico.
    Vásquez WF; Mozumder P; Hernández-Arce J; Berrens RP
    J Environ Manage; 2009 Aug; 90(11):3391-400. PubMed ID: 19525059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A stated preference approach to assessing health care-quality improvements in Palestine: from theoretical validity to policy implications.
    Mataria A; Donaldson C; Luchini S; Moatti JP
    J Health Econ; 2004 Nov; 23(6):1285-311. PubMed ID: 15556246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Making real options really work.
    van Putten AB; MacMillan IC
    Harv Bus Rev; 2004 Dec; 82(12):134-41, 150. PubMed ID: 15605572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. On the possibility of a bridge between CBA and CEA: comments on a paper by Dolan and Edlin.
    Hansen BO; Hougaard JL; Keiding H; Østerdal LP
    J Health Econ; 2004 Sep; 23(5):887-98. PubMed ID: 15353184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing the capital efficiency of healthcare information technologies investments: an econometric perspective.
    Meyer R; Degoulet P
    Yearb Med Inform; 2008; ():114-27. PubMed ID: 18660886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An instrument for measuring the social willingness to pay for health state improvement.
    Richardson J; Iezzi A; Sinha K; Khan MA; Mckie J
    Health Econ; 2014 Jul; 23(7):792-805. PubMed ID: 23824989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The value of a statistical life: a meta-analysis with a mixed effects regression model.
    Bellavance F; Dionne G; Lebeau M
    J Health Econ; 2009 Mar; 28(2):444-64. PubMed ID: 19100640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cost-effectiveness analysis of a community-based diabetes prevention program in Sweden.
    Johansson P; Ostenson CG; Hilding AM; Andersson C; Rehnberg C; Tillgren P
    Int J Technol Assess Health Care; 2009 Jul; 25(3):350-8. PubMed ID: 19619354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended follow-up and spatial analysis of the American Cancer Society study linking particulate air pollution and mortality.
    Krewski D; Jerrett M; Burnett RT; Ma R; Hughes E; Shi Y; Turner MC; Pope CA; Thurston G; Calle EE; Thun MJ; Beckerman B; DeLuca P; Finkelstein N; Ito K; Moore DK; Newbold KB; Ramsay T; Ross Z; Shin H; Tempalski B
    Res Rep Health Eff Inst; 2009 May; (140):5-114; discussion 115-36. PubMed ID: 19627030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The benefits of avoiding cancer (or dying from cancer): Evidence from a four- country study.
    Alberini A; Ščasný M
    J Health Econ; 2018 Jan; 57():249-262. PubMed ID: 28864334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relationship between reliability and size of willingness-to-pay values: a qualitative insight.
    Smith RD
    Health Econ; 2007 Feb; 16(2):211-6. PubMed ID: 16929470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of 'reference goods' in contingent valuation: should we help respondents to 'construct' their willingness to pay?
    Smith RD
    Health Econ; 2007 Dec; 16(12):1319-32. PubMed ID: 17328037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic profile of health investment and the evolution of elderly health.
    Lo TF; Hsieh CR
    Soc Sci Med; 2013 Jan; 76(1):134-42. PubMed ID: 23157932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
    Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
    Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs.
    Jeuland M; Whittington D
    Vaccine; 2009 May; 27(23):3109-20. PubMed ID: 19428925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.